Quoin Pharmaceuticals (QNRX)
NASDAQ:QNRX
QNRX Stock Chart & Stats
$11.72
-$0.04(-5.59%)
At close: 4:00 PM EST
$11.72
-$0.04(-5.59%)
Day’s Range― - ―
52-Week Range$5.01 - $41.80
Previous CloseN/A
Volume155.80K
Average Volume (3M)629.04K
Market Cap
$10.52M
Enterprise Value-$3.81B
Total Cash (Recent Filing)$3.82B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.03
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding1,803,626
10 Day Avg. Volume1,633,105
30 Day Avg. Volume629,040
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-362.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit151.61K
Enterprise Value/Ebitda233.71
Forecast
1Y Price Target
$37.50Price Target Upside219.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.38
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
First-to-market OpportunityEncouraging clinical data and the absence of approved therapies for Netherton syndrome position QRX003 to capture meaningful market share if it becomes the first approved treatment.
Regulatory PathwayFDA indication that a single pivotal Phase 3 study could be sufficient for QRX003 may reduce overall development costs and simplify the path to approval, improving the drug's commercialization timeline.
Trial Design FlexibilityOpenness to alternative designs such as randomized withdrawal or delayed-start enables study approaches better suited to a visible skin disease and could speed patient enrollment while yielding clearer treatment comparisons.
Bears Say
Financing Dependency RiskPlanned reliance on unlocking additional financing tied to favorable regulatory meeting outcomes creates funding risk if meeting minutes do not support a clear approval pathway.
High Evidentiary BarCautious FDA language signals that regulators will likely demand exceptionally robust efficacy and safety data, maintaining significant approval risk for QRX003.
Potential Need For Additional StudiesPhraseology that a single study 'may' suffice implies regulators could require further trials if initial data are not decisive, which would increase development costs and extend timelines.
Quoin Pharmaceuticals News
QNRX FAQ
What was Quoin Pharmaceuticals’s price range in the past 12 months?
Quoin Pharmaceuticals lowest stock price was $5.01 and its highest was $41.80 in the past 12 months.
What is Quoin Pharmaceuticals’s market cap?
Quoin Pharmaceuticals’s market cap is $10.52M.
When is Quoin Pharmaceuticals’s upcoming earnings report date?
Quoin Pharmaceuticals’s upcoming earnings report date is May 13, 2026 which is in 39 days.
How were Quoin Pharmaceuticals’s earnings last quarter?
Quoin Pharmaceuticals released its earnings results on Mar 26, 2026. The company reported -$1.74 earnings per share for the quarter, beating the consensus estimate of -$4.02 by $2.28.
Is Quoin Pharmaceuticals overvalued?
According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued.
Does Quoin Pharmaceuticals pay dividends?
Quoin Pharmaceuticals does not currently pay dividends.
What is Quoin Pharmaceuticals’s EPS estimate?
Quoin Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Quoin Pharmaceuticals have?
Quoin Pharmaceuticals has 1,803,626 shares outstanding.
What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?
Quoin Pharmaceuticals reported an EPS of -$1.74 in its last earnings report, beating expectations of -$4.02. Following the earnings report the stock price went down -18.393%.
Which hedge fund is a major shareholder of Quoin Pharmaceuticals?
Currently, no hedge funds are holding shares in QNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
QNRX Stock 12 Month Forecast
Average Price Target
$37.50
▲(219.97% Upside)
Technical Analysis
Galmed Pharmaceuticals
―
Jaguar Animal Health
―
Adial Pharmaceuticals
―
Alzamend Neuro
―
Calidi Biotherapeutics
―